SOURCE: CDEX Inc.

CDEX Inc.

December 07, 2010 12:46 ET

CDEX's ValiMed G4 System Featured at the 45th Annual ASHP Midyear Conference

Fourth Generation ("G4") System Features Multi-Compound Measurement Capabilities

TUCSON, AZ--(Marketwire - December 7, 2010) - CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced the Company will exhibit its proprietary ValiMed G4 multi-component medication and narcotic detection system, at the 45th Annual Midyear ASHP Clinical Meeting and Exhibition. The ASHP conference is being held at the Anaheim Convention Center in Anaheim, California December 6-8, 2010. The ValiMed G4 system will be featured at booth 1908 at the conference.

The fourth generation of the ValiMed Validation System significantly raises the bar for patient medication safety and pharmaceutical drug loss prevention. The ValiMed G4 provides cutting edge features and benefits over existing systems available in the market. The G4 identifies the drug, the dose, the diluents, and is the first to feature multi-component compound detection. The G4 will have an enhanced software platform for improved accuracy and reliability, while able to perform non-invasive measures of compounds directly through IV bags, syringes and vials, offering lower risk of contamination with increased workflow. In addition to validating high-risk medications before leaving the clinical or pharmacy environment, the ValiMed G4 will also monitor and discourage the diversion of controlled substances by validating the returned or unused narcotics from patient treatment areas or surgery suites. Other applications for the ValiMed G4 system include counterfeit medication monitoring, regulatory compliance and training of clinical and pharmacy personnel.

The ASHP Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacists in the world. With its focus on improving patient care, the conference is attended by more than 20,000 pharmacy professionals from 86 countries. For over four decades, the ASHP Midyear Clinical Meeting has provided health-system pharmacy practitioners with a venue for updating their knowledge, networking with colleagues, enhancing their skills, and learning about the latest products and technologies available in the market.

"The ASHP Midyear conference is the largest marquee venue to showcase our new ValiMed G4 System to a national and international audience of industry professionals. We believe we are the first to offer an affordable advanced measuring system, with multi-component capabilities that will enhance and improve the quality of care that pharmacies and clinical professionals provide. This is the perfect setting for CDEX to showcase the cutting edge technology of our new ValiMed G4 System," commented Jeff Brumfield, CEO and Chairman of CDEX, Inc.

About CDEX
CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit www.cdex-inc.com

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information